Geopolitical shifts and the future of RNA therapeutics: Navigating China’s proposed platform restrictions
As the therapeutic RNA field celebrates a watershed year in 2026—marked by milestone clinical readouts in linear mRNA cancer vaccines, chronic monogenic conditions, and circular RNA in vivo cell engineering—the global biopharmaceutical ecosystem is facing a profound structural realignment. Just as scientific delivery platforms are maturing to cross traditional biological barriers, international policy is erecting new borders. Recent regulatory drafts from Beijing—specifically revisions to China’s technology export controls under announcement no.
Authors
- Paloma H. Giangrande (ORCID: https://orcid.org/0000-0002-6559-3308)
- Cesare Di Nitto (ORCID: https://orcid.org/0009-0006-2319-388X)
Institutions
- Crystal Pharmatech (United States) (US)
Publication Details
- Journal
- Molecular Therapy — Nucleic Acids
- Published
- 2026-11-20
- DOI
- https://doi.org/10.1016/j.omtn.2026.103175
- Primary Topic
- RNA Interference and Gene Delivery
- Type
- article
- Field-Weighted Citation Impact
- 0.00